Skip to main content
Premium Trial:

Request an Annual Quote

Pall India, Spinchrom Ink Indian Distribution Deal

NEW YORK (GenomeWeb News) – Pall today announced an exclusive distribution deal covering India between Pall India and Spinchrom Life Sciences, a division of Spinco Biotech.

Spinchrom, which on focuses on the life sciences and consumables markets, will be the exclusive distributor in India of ForteBio's Blitz system for the label-free analysis of proteins with small sample volumes. ForteBio is a division of Pall Life Sciences and supplies label-free technology for the development of biotherapeutic and pharmaceutical products.

"Given the growing biosimilar and proteomic activity in India, scientists' ability to understand protein interactions is increasingly a key success factor," Sachin Indane, director of Biopharm, Pall India, said in a statement. The Blitz platform, he added, will make label-free protein analysis more accessible in India, furthering biotherapeutic development in the country.

"This partnership enables us to position the innovative Blitz label-free protein analysis technology as a complementary tool to our existing proteomics portfolio, thereby offering customers comprehensive solutions for protein characterization and interaction studies," C. Ravindranath, managing director of the Spinco Group of companies, added.

Financial and other terms of the deal were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.